4. Ringstrom G

Abrahamsson H

Strid H

Simren M Why do subjects with irritable bowel syndrome seek health care for their symptoms?. Scand J Gastroenterol. 42 : 1194-1203 View in Article Scopus (48)

PubMed

Crossref

Google Scholar

5. Hillila MT

Siivola MT

Farkkila MA Comorbidity and use of health-care services among irritable bowel syndrome sufferers. Scand J Gastroenterol. 42 : 799-806 View in Article Scopus (45)

PubMed

Crossref

Google Scholar

6. Locke 3rd, GR

Zinsmeister AR

Fett SL

Melton 3rd, LJ

Talley NJ Overlap of gastrointestinal symptom complexes in a US community. Neurogastroenterol Motil. 17 : 29-34 View in Article Scopus (181)

PubMed

Crossref

Google Scholar

8. Vu J

Kushnir V

Cassell B

Gyawali CP

Sayuk GS The impact of psychiatric and extraintestinal comorbidity on quality of life and bowel symptom burden in functional GI disorders. Neurogastroenterol Motil. 26 : 1323-1332 View in Article Scopus (38)

PubMed

Crossref

Google Scholar

14. Tornblom H

Van Oudenhove L

Sadik R

Abrahamsson H

Tack J

Simren M Colonic transit time and IBS symptoms: what's the link?. Am J Gastroenterol. 107 : 754-760 View in Article Scopus (93)

PubMed

Crossref

Google Scholar

17. Bajor A

Tornblom H

Rudling M

Ung KA

Simren M Increased colonic bile acid exposure: a relevant factor for symptoms and treatment in IBS. Gut. 64 : 84-92 View in Article Scopus (91)

PubMed

Crossref

Google Scholar

19. Ringstrom G

Storsrud S

Posserud I

Lundqvist S

Westman B

Simren M Structured patient education is superior to written information in the management of patients with irritable bowel syndrome: a randomized controlled study. Eur J Gastroenterol Hepatol. 22 : 420-428 View in Article Scopus (55)

PubMed

Crossref

Google Scholar

20. Johannesson E

Simren M

Strid H

Bajor A

Sadik R Physical activity improves symptoms in irritable bowel syndrome: a randomized controlled trial. Am J Gastroenterol. 106 : 915-922 View in Article Scopus (165)

PubMed

Crossref

Google Scholar

21. McKenzie YA

Bowyer RK

Leach H

et al. British Dietetic Association systematic review and evidence-based practice guidelines for the dietary management of irritable bowel syndrome in adults (2016 update). J Hum Nutr Diet. 29 : 549-575 View in Article Scopus (85)

PubMed

Crossref

Google Scholar

22. Johannesson E

Ringstrom G

Abrahamsson H

Sadik R Intervention to increase physical activity in irritable bowel syndrome shows long-term positive effects. World J Gastroenterol. 21 : 600-608 View in Article Scopus (0)

PubMed

Crossref

Google Scholar

23. Ford AC

Quigley EM

Lacy BE

et al. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Am J Gastroenterol. 109 : 1547-1561 View in Article Scopus (361)

PubMed

Crossref

Google Scholar

25. Cann PA

Read NW

Holdsworth CD

Barends D Role of loperamide and placebo in management of irritable bowel syndrome (IBS). Dig Dis Sci. 29 : 239-247 View in Article Scopus (190)

PubMed

Crossref

Google Scholar

26. Ford AC

Moayyedi P

Lacy BE

et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol. 109 : S2-26 View in Article Scopus (335)

PubMed

Crossref

Google Scholar

28. Krause R

Ameen V

Gordon SH

et al. A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS. Am J Gastroenterol. 102 : 1709-1719 View in Article Scopus (73)

PubMed

Crossref

Google Scholar

31. Garsed K

Chernova J

Hastings M

et al. A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea. Gut. 63 : 1617-1625 View in Article Scopus (109)

PubMed

Crossref

Google Scholar

32. Pimentel M

Park S

Mirocha J

Kane SV

Kong Y The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med. 145 : 557-563 View in Article Scopus (382)

PubMed

Crossref

Google Scholar

33. Pimentel M

Lembo A

Chey WD

et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 364 : 22-32 View in Article Scopus (640)

PubMed

Crossref

Google Scholar

35. Menees SB

Maneerattannaporn M

Kim HM

Chey WD The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol. 107 : 28-35 View in Article Scopus (183)

PubMed

Crossref

Google Scholar

39. Camilleri M

Acosta A

Busciglio I

et al. Effect of colesevelam on faecal bile acids and bowel functions in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 41 : 438-448 View in Article Scopus (55)

PubMed

Crossref

Google Scholar

40. Wilcox C

Turner J

Green J Systematic review: the management of chronic diarrhoea due to bile acid malabsorption. Aliment Pharmacol Ther. 39 : 923-939 View in Article Scopus (57)

PubMed

Crossref

Google Scholar

42. Lam C

Tan W

Leighton M

et al. A mechanistic multicentre, parallel group, randomised placebo-controlled trial of mesalazine for the treatment of IBS with diarrhoea (IBS-D). Gut. 65 : 91-99 View in Article Scopus (44)

PubMed

Crossref

Google Scholar

45. Bijkerk CJ

Muris JW

Knottnerus JA

Hoes AW

de Wit NJ Systematic review: the role of different types of fibre in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 19 : 245-251 View in Article Scopus (235)

PubMed

Crossref

Google Scholar

46. Moayyedi P

Quigley EM

Lacy BE

et al. The effect of fiber supplementation on irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol. 109 : 1367-1374 View in Article Scopus (116)

PubMed

Crossref

Google Scholar

47. Belsey JD

Geraint M

Dixon TA Systematic review and meta analysis: polyethylene glycol in adults with non-organic constipation. Int J Clin Pract. 64 : 944-955 View in Article Scopus (47)

PubMed

Crossref

Google Scholar

48. Chapman RW

Stanghellini V

Geraint M

Halphen M Randomized clinical trial: macrogol/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome. Am J Gastroenterol. 108 : 1508-1515 View in Article Scopus (75)

PubMed

Crossref

Google Scholar

50. Chey WD

Lembo AJ

Lavins BJ

et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol. 107 : 1702-1712 View in Article Scopus (261)

PubMed

Crossref

Google Scholar

51. Rao S

Lembo AJ

Shiff SJ

et al. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol. 107 : 1714-1724 View in Article Scopus (228)

PubMed

Crossref

Google Scholar

52. Raschi E

De Ponti F Lubiprostone: pharmacokinetic, pharmacodynamic, safety and regulatory aspects in the treatment of constipation-predominant irritable bowel syndrome. Expert Opin Drug Metab Toxicol. 10 : 293-305 View in Article Scopus (14)

PubMed

Crossref

Google Scholar

53. Drossman DA

Chey WD

Johanson JF

et al. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome–results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther. 29 : 329-341 View in Article Scopus (260)

PubMed

Crossref

Google Scholar

54. Chey WD

Drossman DA

Johanson JF

Scott C

Panas RM

Ueno R Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation. Aliment Pharmacol Ther. 35 : 587-599 View in Article Scopus (79)

PubMed

Crossref

Google Scholar

55. Evans BW

Clark WK

Moore DJ

Whorwell PJ Tegaserod for the treatment of irritable bowel syndrome and chronic constipation. Cochrane Database Syst Rev. 4 ( ) View in Article Google Scholar

56. Tack J

Quigley E

Camilleri M

Vandeplassche L

Kerstens R Efficacy and safety of oral prucalopride in women with chronic constipation in whom laxatives have failed: an integrated analysis. United European Gastroenterol J. 1 : 48-59 View in Article Scopus (33)

PubMed

Crossref

Google Scholar

57. Tack J

Stanghellini V

Dubois D

Joseph A

Vandeplassche L

Kerstens R Effect of prucalopride on symptoms of chronic constipation. Neurogastroenterol Motil. 26 : 21-27 View in Article Scopus (40)

PubMed

Crossref

Google Scholar

58. Annahazi A

Roka R

Rosztoczy A

Wittmann T Role of antispasmodics in the treatment of irritable bowel syndrome. World J Gastroenterol. 20 : 6031-6043 View in Article Scopus (34)

PubMed

Crossref

Google Scholar

59. Ford AC

Talley NJ

Spiegel BM

et al. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ. 337 : a2313 View in Article Scopus (380)

PubMed

Crossref

Google Scholar

60. Ruepert L

Quartero AO

de Wit NJ

van der Heijden GJ

Rubin G

Muris JW Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 8 ( ) View in Article Google Scholar

61. Cash BD

Epstein MS

Shah SM A novel delivery system of peppermint oil is an effective therapy for irritable bowel syndrome symptoms. Dig Dis Sci. 61 : 560-571 View in Article Scopus (62)

PubMed

Crossref

Google Scholar

64. Ford AC

Quigley EM

Lacy BE

et al. Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol. 109 : 1350-1365 View in Article Scopus (254)

PubMed

Crossref

Google Scholar

65. Vahedi H

Merat S

Momtahen S

et al. Clinical trial: the effect of amitriptyline in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 27 : 678-684 View in Article Scopus (92)

PubMed

Crossref

Google Scholar

66. Lunn MP

Hughes RA

Wiffen PJ Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database Syst Rev. 1 ( ) View in Article Google Scholar

67. Gallagher HC

Gallagher RM

Butler M

Buggy DJ

Henman MC Venlafaxine for neuropathic pain in adults. Cochrane Database Syst Rev. 8 ( ) View in Article Google Scholar

68. Agrawal A

Houghton LA

Morris J

et al. Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation. Aliment Pharmacol Ther. 29 : 104-114 View in Article Scopus (204)

PubMed

Crossref

Google Scholar

72. Tzellos TG

Papazisis G

Toulis KA

Sardeli C

Kouvelas D A2delta ligands gabapentin and pregabalin: future implications in daily clinical practice. Hippokratia. 14 : 71-75 View in Article PubMed

Google Scholar

73. Tzellos TG

Toulis KA

Goulis DG

et al. Gabapentin and pregabalin in the treatment of fibromyalgia: a systematic review and a meta-analysis. J Clin Pharm Ther. 35 : 639-656 View in Article Scopus (74)

PubMed

Crossref

Google Scholar

74. Gale JD

Houghton LA Alpha 2 delta (alpha(2)delta) ligands, gabapentin and pregabalin: what is the evidence for potential use of these ligands in irritable bowel syndrome. Front Pharmacol. 2 : 28 View in Article Scopus (36)

PubMed

Crossref

Google Scholar

75. Houghton LA

Fell C

Whorwell PJ

Jones I

Sudworth DP

Gale JD Effect of a second-generation alpha2delta ligand (pregabalin) on visceral sensation in hypersensitive patients with irritable bowel syndrome. Gut. 56 : 1218-1225 View in Article Scopus (143)

PubMed

Crossref

Google Scholar

78. Ljotsson B

Hedman E

Andersson E

et al. Internet-delivered exposure-based treatment vs. stress management for irritable bowel syndrome: a randomized trial. Am J Gastroenterol. 106 : 1481-1491 View in Article Scopus (126)

PubMed

Crossref

Google Scholar

80. Rutten JM

Reitsma JB

Vlieger AM

Benninga MA Gut-directed hypnotherapy for functional abdominal pain or irritable bowel syndrome in children: a systematic review. Arch Dis Child. 98 : 252-257 View in Article Scopus (50)

PubMed

Crossref

Google Scholar

81. Moser G

Tragner S

Gajowniczek EE

et al. Long-term success of GUT-directed group hypnosis for patients with refractory irritable bowel syndrome: a randomized controlled trial. Am J Gastroenterol. 108 : 602-609 View in Article Scopus (77)

PubMed

Crossref

Google Scholar